GGrantIndex
← Search

CORE--CLINICAL TRIALS AND PROTOCOL REVIEW AND MONITORING SYSTEM

$0P30FY2001CANIH

Ohio State University, Columbus OH

Investigators

Linked publications, trials & patents

Trial NCT04662645Trial NCT04602026Trial NCT04567706Trial NCT04454086Trial NCT04439006Trial NCT04329962Trial NCT04269837Trial NCT04267874Trial NCT04233567Trial NCT04229381Trial NCT04220684Trial NCT04205903Trial NCT04205240Trial NCT04205071Trial NCT04164069Trial NCT04140513Trial NCT04120454Trial NCT04116970Trial NCT04115163Trial NCT04063410Trial NCT04049539Trial NCT04032106Trial NCT03975231Trial NCT03943342Trial NCT03892044Trial NCT03868423Trial NCT03858855Trial NCT03824327Trial NCT03798639Trial NCT03786354Trial NCT03749018Trial NCT03728361Trial NCT03719092Trial NCT03715959Trial NCT03711890Trial NCT03691350Trial NCT03665675Trial NCT03656835Trial NCT03654638Trial NCT03631641Trial NCT03611205Trial NCT03583424Trial NCT03568526Trial NCT03537599Trial NCT03532581Trial NCT03525925Trial NCT03513562Trial NCT03463460Trial NCT03460483Trial NCT03447808Trial NCT03409432Trial NCT03372720Trial NCT03333746Trial NCT03328936Trial NCT03307044Trial NCT03287453Trial NCT02960100Trial NCT02950220Trial NCT02942524Trial NCT02940301Trial NCT02927899Trial NCT02835755Trial NCT02831582Trial NCT02812693Trial NCT02795104Trial NCT02791737Trial NCT02760030Trial NCT02439255Trial NCT02303392Trial NCT02101944Trial NCT02015117Trial NCT01964924Trial NCT01955499Trial NCT01861314Trial NCT01841723Trial NCT01811212Trial NCT01533194Trial NCT01519414Trial NCT01515176Trial NCT01468896Trial NCT01425879Trial NCT01351896Trial NCT01281124Trial NCT01280058Trial NCT01254617Trial NCT01254578Trial NCT01251874Trial NCT01249430Trial NCT01238133Trial NCT01132586Trial NCT01130506Trial NCT01129193Trial NCT01126502Trial NCT01076556Trial NCT01017640Trial NCT00735930Trial NCT00703300Trial NCT00602277Trial NCT00563290Trial NCT00499473

Abstract

The CCC Clinical Trials Office [CTO] supports the centralized administration of protocol development, review, implementation, monitoring, regulatory compliance, and quality assurance. The CTO was established in September 1998 by consolidating resources of the Interdisciplinary Oncology Unit, the Ambulatory Oncology Unit, and the Office for Quality Assurance for Clinical Trials. Rebecca Jackson, M.D. was named CTO Director and five full-time staff members [2 research nurses, 2 protocol compliance staff, and a secretary] were initially appointed using a combination of CCSG and institutional funding. The CTO coordinates the efforts of 25 additional interactive clinical trials staff funded by cooperative group contracts, grants, and institutional funds. The CTO initially reviewed existing clinical research policies and procedures and developed formal standard operating procedures for the conduct of all clinical trials at the CCC. The protocol review process was strengthened by reorganizing the Clinical Scientific Review Committee [CSRC] and formalizing review criteria. The CTO assists investigators in developing new studies by informing them of the protocol review process, by providing protocol outlines and templates, and by referring investigators to collaborators with appropriate expertise. The CTO helps the investigators through the review processes of the CSRC and IRB by preparing protocol submission documents and consent forms. Following protocol approval and implementation, the CTO maintains all study regulatory documents in a central location, distributes protocols to interested investigators, and supports a Clinical Research Information System which allows centralized protocol registration and report generation. CTO staff also screen patients for trial eligibility to increase the proportion of patients registered on clinical trials. The CTO prepares protocol performance reports for the CSRC in support of monitoring the scientific progress of all studies. Protocol compliance staff of the CTO conduct a formal audit program using random selection of studies and patients to review protocol compliance and data accuracy. Educational programs developed and conducted by the CTO train clinical and data management staff in the proper application of Good Clinical Practices. The quest for CCSG support for 2.6 FTE for the CTO represents support of 8.7% of the total CTO effort in centrally managing CCC clinical trials.

View original record on NIH RePORTER →